Why might treatment for inflammation fail to slow human aging?

HERETICAL, conditional: In a prospectively specified population of cycling epithelial progenitors from aging humans, endogenous IL-11 signaling may preserve DNA-break repair fidelity. Blocking IL-11 could shift repair toward polymerase-theta-mediated end joining, increasing newly generated deletions and rearrangements in surviving descendants despite reduced inflammatory injury, adequate early wound closure and mature epithelial function, and initially preserved pathogen clearance. Each concurrent outcome requires separate demonstration. The proposed fidelity defect concerns repair of comparable damage substrates within tracked lineages; more errors caused solely by changed lesion production, location or complexity would not establish it. Persistent genomic damage could later increase malignant or organ-failure transitions within SPV_3 and offset an independently demonstrated beneficial effect. Persistence, clinical consequence and sufficient magnitude for cancellation remain additional conditional links.

Do not define susceptibility by subsequently observing excess errors. Under randomized donor-paired control, ligand-neutralization and inducible IL11RA-loss conditions, compare characterized nonlethal lesion classes at matched genomic sites. Characterize initial break-end structure and chemistry, clustered or associated damage, complexity, local chromatin and replication context, lesion induction timing and burden. Equal break counts alone are insufficient. Combine a defined-break reporter with direct measurements at endogenous loci, including matched-site induced lesions and separately characterized ordinary endogenous damage where feasible. Follow lesion processing over time: treatment-induced end processing may itself mediate repair choice and must not automatically be matched away. Estimate the total treatment effect separately from repair accuracy under experimentally comparable initial substrates. Retain unchallenged cultures and the complete randomized starting population. The focal prediction is excess de novo structural repair errors for comparable initial lesion classes before differential expansion explains the result, with orthogonal IL-11 perturbations and a validated physiological, perturbation-compatible rescue reversing that excess. Orthogonal polymerase-theta perturbation should identify its contribution while accurate repair, other erroneous repair, persistent breaks, arrest, death and lineage loss remain accounted for per initial lesion and starting cell; descendant-level estimates are additional denominators. A reduced microhomology signature accompanied by worse unresolved damage or lineage survival does not demonstrate improved fidelity. The substrate/selection alternative predicts that differences follow lesion characteristics, lesion production, division history or lineage recovery, with equivalent accuracy for comparable substrates. If initial substrates cannot be adequately characterized or controlled, fidelity versus substrate mediation remains unresolved. Separately demonstrate reduced inflammatory injury, adequate early epithelial replacement and mature function, and preserved laboratory pathogen clearance at the same exposure. A fidelity defect alone supports only part of the frozen conjunction. Sensitive bounded equivalence constrains the prospectively defined population and tested lesion classes; it does not justify retrospectively excluding nonresponders. Receptor competition, communication defects and immune injury may coexist or lie upstream.

Independently perturb sender repair state across independently varied receiver starting states while controlling initial injury, matrix, nutrients and nonspecific support. Measure whether endogenous IL-11 output changes with sender state and whether selective sender IL-11 loss and receiver IL11RA loss interrupt the attributable response, with appropriate perturbation-alone and restoration controls. Monitor other secretions, nutrient changes, matrix changes and material transport. Then randomize correct alignment versus mismatch between actual partner state and delivered IL-11-dependent signal. Compare contingent signals with yoked signals from independently assigned, appropriately matched partners, shuffled signals and state-independent schedules. Balance waveform amplitude, duration, integrated exposure, pulse statistics and relevant delay distributions where feasible, while retaining state–signal alignment as the changed variable. Measure realized receptor activation and adaptation without forcing complete mediator histories to equality. The focal prediction is that mismatch impairs complementary mature differentiation and barrier recovery and correct alignment reverses this penalty while isolated competence and lower mean inflammatory signaling remain separately verified. A favorable separation additionally requires maintained reduction in actual inflammatory injury during rescue, with cell-specific exposure, peaks and duration assessed; a lower average can conceal damaging local pulses. Equivalent recovery with an appropriately chosen state-independent schedule after receiver readiness, shared injury history and support are addressed favors the alternative that actual partner state adds no necessary guidance. Unmatched replay superiority, equal integrated ligand and pulse-versus-tonic superiority are insufficient. Demonstrated endogenous feedback supports the biological coupling claim but does not establish novelty beyond reciprocal paracrine support or validate the consensus equation. For the model, calibrate coordinates and parameters independently and predict held-out changes in sender state, communication edges, delays and mature functional recovery; compare these predictions with receiver-only exposure/support models.

Interleukin-11 may reflect injury while exerting little control over human aging predicts instead: Test limited benefit and limited harm separately after a prospectively justified transient interval. At demonstrated tissue exposure, validated damage and functional trajectories should lie within prespecified consequential equivalence bounds, while repair, pathogen control and adverse channels independently meet their own bounds. Aggregate nonsignificance supports neither neutrality nor cancellation. If a candidate cost appears, use randomized control C, blockade B, rescue alone R and blockade-plus-rescue BR arms. Verify comparable blockade exposure and target engagement in B and BR, demonstrate adverse-mediator removal, and measure the rescue's independent effects. For Y oriented so that higher is better, estimate Δ0=Y_B−Y_C, ΔR=Y_BR−Y_R and interaction I=ΔR−Δ0. A favorable BR−B contrast does not identify blockade benefit; a favorable ΔR or interaction does not alone identify cancellation. The prediction that no consequential blockade benefit emerges under rescue is conditional on rescue preserving the relevant biological context, beneficial pathways and effect modifiers apart from removing a demonstrated blockade-induced harmful component. Test that preservation using direct mediator, cell-state, exposure and beneficial-channel measurements; rescue specificity by itself does not establish it. If rescue creates a new permissive state or interaction, benefit under rescue remains compatible with neutrality in the original setting. To support cancellation, demonstrate beneficial and harmful effects of blockade before rescue at the same exposure and relevant duration, then show selective removal of the harmful component while the beneficial route remains operative. Even with a factorial interaction, alternative synergy requires consideration. Failure to uncover benefit remains inconclusive when rescue is incomplete, context changes, exposure differs, precision is inadequate or follow-up is too short. Marker behavior, disease-specific amplification and redundancy require additional causal tests and are not identified by equivalence alone.

Blocking interleukin-11 may free shared receptors to sustain harmful competing signals predicts instead: In a characterized older-human epithelial population under fixed defined ligands, an occupancy-releasing blocker should produce a quantitatively compatible loss of gp130 from IL-11 complexes and gain in specified competing complexes within the same accessible pool. Resolve individual cells and relevant membrane compartments with sufficient temporal resolution to establish exchange compatibility before the competing signal and functional cost. Reciprocal population or whole-cell averages from different subpopulations or disconnected compartments are insufficient. Use convergent minimally perturbing complex and localization measurements and, where validated, tracking of component movement or a pool-selective perturbation to test access and exchange. Account for free, other-bound, incoming, internalized and recycled components rather than assume direct one-for-one transfer. Compare blocker modalities at comparable IL-11 inhibition; occupancy-retaining inhibition need not redistribute gp130. Independently demonstrate a limiting range where additional accessible surface gp130 increases competing-complex assembly and a nonlimiting range where further increases do not materially increase assembly, with adequate precision and unsaturated detection. Independently verify that downstream and functional readouts retain responsive range. Quantify receptor abundances, ratios, localization, baseline complexes and trafficking across the manipulation. Only the conjunction of same-pool allocation, validated limitation and its relief, responsive readouts and functional mediation supports competition. Controlled occupancy restoration should reverse allocation, subject to controls for its effects on signaling and trafficking. Competing-receptor interruption should remove the attributable cost while IL-11 suppression persists, with interruption-alone controls. Rescue or attenuation at high gp130 alone does not distinguish allocation from feedback, saturation or trafficking. Follow the acute step into sustained harmful differentiation or function and post-transient deterioration; neutral, beneficial or transient allocation does not confirm the harmful extension.

Interleukin-11 blockade may change displayed self-peptides and trigger immune injury predicts instead: First establish epithelial IL-11 responsiveness and a reproducible change in endogenous displayed self-peptide species under orthogonal epithelial IL-11 perturbations. Identify peptide sequence, relevant modifications and presenting HLA molecule. Compare baseline and treated samples with quantitative recovery controls, targeted baseline measurements and explicit detection limits. Baseline non-detection cannot establish absolute absence. Constrain baseline abundance and compare it with independently characterized recognition over physiological display ranges, testing whether increased abundance of an unchanged species can explain recognition. If that account remains plausible, report identity change as unresolved; do not count new detection as confirmation or reject broader antigen-specific harm. At comparable cell composition and total presentation, the full chain predicts altered proteasomal processing before the repertoire change, recognition by a baseline memory population with independently demonstrated cognate specificity, and then selective killing. Measure source proteins, direct cleavage products, transport/loading, HLA composition, turnover and cell state. Selective processing intervention should prevent the identity change and attributable injury while preserving epithelial fitness; physiological downstream reconstitution should restore the specified peptide–HLA complex and recognition. Broad proteasome inhibition is insufficient. Separately remove and restore the implicated peptide–HLA–T-cell-receptor interaction at endogenous-range display, preserving source-protein function and IL-11 blockade. Include epithelial-only, T-cell-only, coculture, perturbation-alone and pretreatment/washout controls with residual drug and pathway-state measurements. Demonstrate baseline memory phenotype, specificity, tissue access and response under prospectively defined physiological activation support; strong artificial stimulation cannot establish the in-tissue conjunction. Measure preserved intrinsic repair, adequate laboratory pathogen killing and reduced soluble inflammatory markers separately. Follow repeated killing, replacement, immune restraint and barrier function before claiming persistent injury. Identity change without processing mediation leaves the proteasomal link open; antigen-specific killing without an identified switch supports only a partial or alternative route. Injury independent of the specified recognition pair favors stress, bystander activation or generalized susceptibility.

CROSS-DOMAIN TRANSFER, conditional: In a defined aging-human epithelial–stromal repair unit, endogenous IL-11-dependent communication may couple distinct receptor-positive populations toward compatible repair-completion states. A population's repair state could alter an IL-11 signal that appropriately changes its partner's progression. Blockade could disrupt this relationship while preserving isolated repair competence under comparable support, causing premature termination or inappropriate continuation of collective repair. Persistent functional incompatibility could prolong barrier deficits and secondary injury despite lower mean inflammatory signaling. The specific claim concerns the causal value of correct alignment between actual partner state and delivered signal, physically implemented through ligand exposure and receptor response. Ordinary state-dependent paracrine signaling may implement this relationship. Restoring alignment could shorten function-specific SPV_4 recovery while retaining reduced harmful inflammatory injury, but this separation must be demonstrated through injury and function, not inferred from lower mean signaling.

Independently perturb sender repair state across independently varied receiver starting states while controlling initial injury, matrix, nutrients and nonspecific support. Measure whether endogenous IL-11 output changes with sender state and whether selective sender IL-11 loss and receiver IL11RA loss interrupt the attributable response, with appropriate perturbation-alone and restoration controls. Monitor other secretions, nutrient changes, matrix changes and material transport. Then randomize correct alignment versus mismatch between actual partner state and delivered IL-11-dependent signal. Compare contingent signals with yoked signals from independently assigned, appropriately matched partners, shuffled signals and state-independent schedules. Balance waveform amplitude, duration, integrated exposure, pulse statistics and relevant delay distributions where feasible, while retaining state–signal alignment as the changed variable. Measure realized receptor activation and adaptation without forcing complete mediator histories to equality. The focal prediction is that mismatch impairs complementary mature differentiation and barrier recovery and correct alignment reverses this penalty while isolated competence and lower mean inflammatory signaling remain separately verified. A favorable separation additionally requires maintained reduction in actual inflammatory injury during rescue, with cell-specific exposure, peaks and duration assessed; a lower average can conceal damaging local pulses. Equivalent recovery with an appropriately chosen state-independent schedule after receiver readiness, shared injury history and support are addressed favors the alternative that actual partner state adds no necessary guidance. Unmatched replay superiority, equal integrated ligand and pulse-versus-tonic superiority are insufficient. Demonstrated endogenous feedback supports the biological coupling claim but does not establish novelty beyond reciprocal paracrine support or validate the consensus equation. For the model, calibrate coordinates and parameters independently and predict held-out changes in sender state, communication edges, delays and mature functional recovery; compare these predictions with receiver-only exposure/support models.

Do not define susceptibility by subsequently observing excess errors. Under randomized donor-paired control, ligand-neutralization and inducible IL11RA-loss conditions, compare characterized nonlethal lesion classes at matched genomic sites. Characterize initial break-end structure and chemistry, clustered or associated damage, complexity, local chromatin and replication context, lesion induction timing and burden. Equal break counts alone are insufficient. Combine a defined-break reporter with direct measurements at endogenous loci, including matched-site induced lesions and separately characterized ordinary endogenous damage where feasible. Follow lesion processing over time: treatment-induced end processing may itself mediate repair choice and must not automatically be matched away. Estimate the total treatment effect separately from repair accuracy under experimentally comparable initial substrates. Retain unchallenged cultures and the complete randomized starting population. The focal prediction is excess de novo structural repair errors for comparable initial lesion classes before differential expansion explains the result, with orthogonal IL-11 perturbations and a validated physiological, perturbation-compatible rescue reversing that excess. Orthogonal polymerase-theta perturbation should identify its contribution while accurate repair, other erroneous repair, persistent breaks, arrest, death and lineage loss remain accounted for per initial lesion and starting cell; descendant-level estimates are additional denominators. A reduced microhomology signature accompanied by worse unresolved damage or lineage survival does not demonstrate improved fidelity. The substrate/selection alternative predicts that differences follow lesion characteristics, lesion production, division history or lineage recovery, with equivalent accuracy for comparable substrates. If initial substrates cannot be adequately characterized or controlled, fidelity versus substrate mediation remains unresolved. Separately demonstrate reduced inflammatory injury, adequate early epithelial replacement and mature function, and preserved laboratory pathogen clearance at the same exposure. A fidelity defect alone supports only part of the frozen conjunction. Sensitive bounded equivalence constrains the prospectively defined population and tested lesion classes; it does not justify retrospectively excluding nonresponders. Receptor competition, communication defects and immune injury may coexist or lie upstream.

Interleukin-11 may reflect injury while exerting little control over human aging predicts instead: Test limited benefit and limited harm separately after a prospectively justified transient interval. At demonstrated tissue exposure, validated damage and functional trajectories should lie within prespecified consequential equivalence bounds, while repair, pathogen control and adverse channels independently meet their own bounds. Aggregate nonsignificance supports neither neutrality nor cancellation. If a candidate cost appears, use randomized control C, blockade B, rescue alone R and blockade-plus-rescue BR arms. Verify comparable blockade exposure and target engagement in B and BR, demonstrate adverse-mediator removal, and measure the rescue's independent effects. For Y oriented so that higher is better, estimate Δ0=Y_B−Y_C, ΔR=Y_BR−Y_R and interaction I=ΔR−Δ0. A favorable BR−B contrast does not identify blockade benefit; a favorable ΔR or interaction does not alone identify cancellation. The prediction that no consequential blockade benefit emerges under rescue is conditional on rescue preserving the relevant biological context, beneficial pathways and effect modifiers apart from removing a demonstrated blockade-induced harmful component. Test that preservation using direct mediator, cell-state, exposure and beneficial-channel measurements; rescue specificity by itself does not establish it. If rescue creates a new permissive state or interaction, benefit under rescue remains compatible with neutrality in the original setting. To support cancellation, demonstrate beneficial and harmful effects of blockade before rescue at the same exposure and relevant duration, then show selective removal of the harmful component while the beneficial route remains operative. Even with a factorial interaction, alternative synergy requires consideration. Failure to uncover benefit remains inconclusive when rescue is incomplete, context changes, exposure differs, precision is inadequate or follow-up is too short. Marker behavior, disease-specific amplification and redundancy require additional causal tests and are not identified by equivalence alone.

Blocking interleukin-11 may free shared receptors to sustain harmful competing signals predicts instead: In a characterized older-human epithelial population under fixed defined ligands, an occupancy-releasing blocker should produce a quantitatively compatible loss of gp130 from IL-11 complexes and gain in specified competing complexes within the same accessible pool. Resolve individual cells and relevant membrane compartments with sufficient temporal resolution to establish exchange compatibility before the competing signal and functional cost. Reciprocal population or whole-cell averages from different subpopulations or disconnected compartments are insufficient. Use convergent minimally perturbing complex and localization measurements and, where validated, tracking of component movement or a pool-selective perturbation to test access and exchange. Account for free, other-bound, incoming, internalized and recycled components rather than assume direct one-for-one transfer. Compare blocker modalities at comparable IL-11 inhibition; occupancy-retaining inhibition need not redistribute gp130. Independently demonstrate a limiting range where additional accessible surface gp130 increases competing-complex assembly and a nonlimiting range where further increases do not materially increase assembly, with adequate precision and unsaturated detection. Independently verify that downstream and functional readouts retain responsive range. Quantify receptor abundances, ratios, localization, baseline complexes and trafficking across the manipulation. Only the conjunction of same-pool allocation, validated limitation and its relief, responsive readouts and functional mediation supports competition. Controlled occupancy restoration should reverse allocation, subject to controls for its effects on signaling and trafficking. Competing-receptor interruption should remove the attributable cost while IL-11 suppression persists, with interruption-alone controls. Rescue or attenuation at high gp130 alone does not distinguish allocation from feedback, saturation or trafficking. Follow the acute step into sustained harmful differentiation or function and post-transient deterioration; neutral, beneficial or transient allocation does not confirm the harmful extension.

Interleukin-11 blockade may change displayed self-peptides and trigger immune injury predicts instead: First establish epithelial IL-11 responsiveness and a reproducible change in endogenous displayed self-peptide species under orthogonal epithelial IL-11 perturbations. Identify peptide sequence, relevant modifications and presenting HLA molecule. Compare baseline and treated samples with quantitative recovery controls, targeted baseline measurements and explicit detection limits. Baseline non-detection cannot establish absolute absence. Constrain baseline abundance and compare it with independently characterized recognition over physiological display ranges, testing whether increased abundance of an unchanged species can explain recognition. If that account remains plausible, report identity change as unresolved; do not count new detection as confirmation or reject broader antigen-specific harm. At comparable cell composition and total presentation, the full chain predicts altered proteasomal processing before the repertoire change, recognition by a baseline memory population with independently demonstrated cognate specificity, and then selective killing. Measure source proteins, direct cleavage products, transport/loading, HLA composition, turnover and cell state. Selective processing intervention should prevent the identity change and attributable injury while preserving epithelial fitness; physiological downstream reconstitution should restore the specified peptide–HLA complex and recognition. Broad proteasome inhibition is insufficient. Separately remove and restore the implicated peptide–HLA–T-cell-receptor interaction at endogenous-range display, preserving source-protein function and IL-11 blockade. Include epithelial-only, T-cell-only, coculture, perturbation-alone and pretreatment/washout controls with residual drug and pathway-state measurements. Demonstrate baseline memory phenotype, specificity, tissue access and response under prospectively defined physiological activation support; strong artificial stimulation cannot establish the in-tissue conjunction. Measure preserved intrinsic repair, adequate laboratory pathogen killing and reduced soluble inflammatory markers separately. Follow repeated killing, replacement, immune restraint and barrier function before claiming persistent injury. Identity change without processing mediation leaves the proteasomal link open; antigen-specific killing without an identified switch supports only a partial or alternative route. Injury independent of the specified recognition pair favors stress, bystander activation or generalized susceptibility.

PHENOMENON-DOESN'T-EXIST, conditional: The proposed human tradeoff between substantial IL-11-mediated aging benefit and consequential repair or defense harm may be absent. In ordinary human aging, elevated IL-11 could predominantly report existing injury or amplify selected disease manifestations while the processes governing continued multisystem damage proceed largely independently. Within specified tissues, exposures and durations, blockade could genuinely suppress its pathway and possibly improve a local disease manifestation, yet produce neither substantial slowing of aging nor a consequential compensating repair or infection cost. Relevant SPV_1 components would remain close to comparable untreated trajectories because the pathway has limited control over them. Injury reporting and disease-specific amplification are distinct possible explanations. Redundancy is a separate competing explanation for apparent neutrality. Neutrality in this original setting makes no unconditional prediction about blockade after another intervention changes biological effect dependence.

At demonstrated tissue exposure, validated damage and functional trajectories should lie within prespecified consequential equivalence bounds, while repair, pathogen control and adverse channels independently meet their own bounds. Aggregate nonsignificance supports neither neutrality nor cancellation. If a candidate cost appears, use randomized control C, blockade B, rescue alone R and blockade-plus-rescue BR arms. Verify comparable blockade exposure and target engagement in B and BR, demonstrate adverse-mediator removal, and measure the rescue's independent effects. For Y oriented so that higher is better, estimate Δ0=Y_B−Y_C, ΔR=Y_BR−Y_R and interaction I=ΔR−Δ0. A favorable BR−B contrast does not identify blockade benefit; a favorable ΔR or interaction does not alone identify cancellation. The prediction that no consequential blockade benefit emerges under rescue is conditional on rescue preserving the relevant biological context, beneficial pathways and effect modifiers apart from removing a demonstrated blockade-induced harmful component. Test that preservation using direct mediator, cell-state, exposure and beneficial-channel measurements; rescue specificity by itself does not establish it. If rescue creates a new permissive state or interaction, benefit under rescue remains compatible with neutrality in the original setting. To support cancellation, demonstrate beneficial and harmful effects of blockade before rescue at the same exposure and relevant duration, then show selective removal of the harmful component while the beneficial route remains operative. Even with a factorial interaction, alternative synergy requires consideration. Failure to uncover benefit remains inconclusive when rescue is incomplete, context changes, exposure differs, precision is inadequate or follow-up is too short. Marker behavior, disease-specific amplification and redundancy require additional causal tests and are not identified by equivalence alone.

Do not define susceptibility by subsequently observing excess errors. Under randomized donor-paired control, ligand-neutralization and inducible IL11RA-loss conditions, compare characterized nonlethal lesion classes at matched genomic sites. Characterize initial break-end structure and chemistry, clustered or associated damage, complexity, local chromatin and replication context, lesion induction timing and burden. Equal break counts alone are insufficient. Combine a defined-break reporter with direct measurements at endogenous loci, including matched-site induced lesions and separately characterized ordinary endogenous damage where feasible. Follow lesion processing over time: treatment-induced end processing may itself mediate repair choice and must not automatically be matched away. Estimate the total treatment effect separately from repair accuracy under experimentally comparable initial substrates. Retain unchallenged cultures and the complete randomized starting population. The focal prediction is excess de novo structural repair errors for comparable initial lesion classes before differential expansion explains the result, with orthogonal IL-11 perturbations and a validated physiological, perturbation-compatible rescue reversing that excess. Orthogonal polymerase-theta perturbation should identify its contribution while accurate repair, other erroneous repair, persistent breaks, arrest, death and lineage loss remain accounted for per initial lesion and starting cell; descendant-level estimates are additional denominators. A reduced microhomology signature accompanied by worse unresolved damage or lineage survival does not demonstrate improved fidelity. The substrate/selection alternative predicts that differences follow lesion characteristics, lesion production, division history or lineage recovery, with equivalent accuracy for comparable substrates. If initial substrates cannot be adequately characterized or controlled, fidelity versus substrate mediation remains unresolved. Separately demonstrate reduced inflammatory injury, adequate early epithelial replacement and mature function, and preserved laboratory pathogen clearance at the same exposure. A fidelity defect alone supports only part of the frozen conjunction. Sensitive bounded equivalence constrains the prospectively defined population and tested lesion classes; it does not justify retrospectively excluding nonresponders. Receptor competition, communication defects and immune injury may coexist or lie upstream.

Disrupted interleukin-11 feedback may uncouple epithelial and stromal repair predicts instead: First identify a native responsive older-human lung epithelial–stromal sender–receiver pair. Independently perturb sender repair state across independently varied receiver starting states while controlling initial injury, matrix, nutrients and nonspecific support. Measure whether endogenous IL-11 output changes with sender state and whether selective sender IL-11 loss and receiver IL11RA loss interrupt the attributable response, with appropriate perturbation-alone and restoration controls. Monitor other secretions, nutrient changes, matrix changes and material transport. Then randomize correct alignment versus mismatch between actual partner state and delivered IL-11-dependent signal. Compare contingent signals with yoked signals from independently assigned, appropriately matched partners, shuffled signals and state-independent schedules. Balance waveform amplitude, duration, integrated exposure, pulse statistics and relevant delay distributions where feasible, while retaining state–signal alignment as the changed variable. Measure realized receptor activation and adaptation without forcing complete mediator histories to equality. The focal prediction is that mismatch impairs complementary mature differentiation and barrier recovery and correct alignment reverses this penalty while isolated competence and lower mean inflammatory signaling remain separately verified. A favorable separation additionally requires maintained reduction in actual inflammatory injury during rescue, with cell-specific exposure, peaks and duration assessed; a lower average can conceal damaging local pulses. Equivalent recovery with an appropriately chosen state-independent schedule after receiver readiness, shared injury history and support are addressed favors the alternative that actual partner state adds no necessary guidance. Unmatched replay superiority, equal integrated ligand and pulse-versus-tonic superiority are insufficient. Demonstrated endogenous feedback supports the biological coupling claim but does not establish novelty beyond reciprocal paracrine support or validate the consensus equation. For the model, calibrate coordinates and parameters independently and predict held-out changes in sender state, communication edges, delays and mature functional recovery; compare these predictions with receiver-only exposure/support models.

Blocking interleukin-11 may free shared receptors to sustain harmful competing signals predicts instead: In a characterized older-human epithelial population under fixed defined ligands, an occupancy-releasing blocker should produce a quantitatively compatible loss of gp130 from IL-11 complexes and gain in specified competing complexes within the same accessible pool. Resolve individual cells and relevant membrane compartments with sufficient temporal resolution to establish exchange compatibility before the competing signal and functional cost. Reciprocal population or whole-cell averages from different subpopulations or disconnected compartments are insufficient. Use convergent minimally perturbing complex and localization measurements and, where validated, tracking of component movement or a pool-selective perturbation to test access and exchange. Account for free, other-bound, incoming, internalized and recycled components rather than assume direct one-for-one transfer. Compare blocker modalities at comparable IL-11 inhibition; occupancy-retaining inhibition need not redistribute gp130. Independently demonstrate a limiting range where additional accessible surface gp130 increases competing-complex assembly and a nonlimiting range where further increases do not materially increase assembly, with adequate precision and unsaturated detection. Independently verify that downstream and functional readouts retain responsive range. Quantify receptor abundances, ratios, localization, baseline complexes and trafficking across the manipulation. Only the conjunction of same-pool allocation, validated limitation and its relief, responsive readouts and functional mediation supports competition. Controlled occupancy restoration should reverse allocation, subject to controls for its effects on signaling and trafficking. Competing-receptor interruption should remove the attributable cost while IL-11 suppression persists, with interruption-alone controls. Rescue or attenuation at high gp130 alone does not distinguish allocation from feedback, saturation or trafficking. Follow the acute step into sustained harmful differentiation or function and post-transient deterioration; neutral, beneficial or transient allocation does not confirm the harmful extension.

Interleukin-11 blockade may change displayed self-peptides and trigger immune injury predicts instead: First establish epithelial IL-11 responsiveness and a reproducible change in endogenous displayed self-peptide species under orthogonal epithelial IL-11 perturbations. Identify peptide sequence, relevant modifications and presenting HLA molecule. Compare baseline and treated samples with quantitative recovery controls, targeted baseline measurements and explicit detection limits. Baseline non-detection cannot establish absolute absence. Constrain baseline abundance and compare it with independently characterized recognition over physiological display ranges, testing whether increased abundance of an unchanged species can explain recognition. If that account remains plausible, report identity change as unresolved; do not count new detection as confirmation or reject broader antigen-specific harm. At comparable cell composition and total presentation, the full chain predicts altered proteasomal processing before the repertoire change, recognition by a baseline memory population with independently demonstrated cognate specificity, and then selective killing. Measure source proteins, direct cleavage products, transport/loading, HLA composition, turnover and cell state. Selective processing intervention should prevent the identity change and attributable injury while preserving epithelial fitness; physiological downstream reconstitution should restore the specified peptide–HLA complex and recognition. Broad proteasome inhibition is insufficient. Separately remove and restore the implicated peptide–HLA–T-cell-receptor interaction at endogenous-range display, preserving source-protein function and IL-11 blockade. Include epithelial-only, T-cell-only, coculture, perturbation-alone and pretreatment/washout controls with residual drug and pathway-state measurements. Demonstrate baseline memory phenotype, specificity, tissue access and response under prospectively defined physiological activation support; strong artificial stimulation cannot establish the in-tissue conjunction. Measure preserved intrinsic repair, adequate laboratory pathogen killing and reduced soluble inflammatory markers separately. Follow repeated killing, replacement, immune restraint and barrier function before claiming persistent injury. Identity change without processing mediation leaves the proteasomal link open; antigen-specific killing without an identified switch supports only a partial or alternative route. Injury independent of the specified recognition pair favors stress, bystander activation or generalized susceptibility.

SCOUT from molecular assembly thermodynamics, conditional: In a subset of aging-human cells, IL-11 receptor complexes may occupy a consequential fraction of a functionally limiting shared surface gp130 pool. An IL-11 blocker that actually reduces this occupancy could release gp130 for a specified coexpressed competing cytokine receptor system, such as a directly verified human oncostatin-M system, increasing its signal while IL-11 activity falls. The complexes must access the same exchangeable pool within the relevant cells and membrane compartments. If the alternative signal maintains injury or disrupts differentiation in those cells, redistribution could prevent improvement in a corresponding SPV_1 component. Physiological occupancy, localization, access and assembly kinetics are prerequisites. Receptor coexpression, shared-subunit naming and successful signaling inhibition alone establish none of them. Circulating cytokine changes and multicellular communication are unnecessary for the proposed cell-intrinsic allocation step.

Resolve individual cells and relevant membrane compartments with sufficient temporal resolution to establish exchange compatibility before the competing signal and functional cost. Reciprocal population or whole-cell averages from different subpopulations or disconnected compartments are insufficient. Use convergent minimally perturbing complex and localization measurements and, where validated, tracking of component movement or a pool-selective perturbation to test access and exchange. Account for free, other-bound, incoming, internalized and recycled components rather than assume direct one-for-one transfer. Compare blocker modalities at comparable IL-11 inhibition; occupancy-retaining inhibition need not redistribute gp130. Independently demonstrate a limiting range where additional accessible surface gp130 increases competing-complex assembly and a nonlimiting range where further increases do not materially increase assembly, with adequate precision and unsaturated detection. Independently verify that downstream and functional readouts retain responsive range. Quantify receptor abundances, ratios, localization, baseline complexes and trafficking across the manipulation. Only the conjunction of same-pool allocation, validated limitation and its relief, responsive readouts and functional mediation supports competition. Controlled occupancy restoration should reverse allocation, subject to controls for its effects on signaling and trafficking. Competing-receptor interruption should remove the attributable cost while IL-11 suppression persists, with interruption-alone controls. Rescue or attenuation at high gp130 alone does not distinguish allocation from feedback, saturation or trafficking. Follow the acute step into sustained harmful differentiation or function and post-transient deterioration; neutral, beneficial or transient allocation does not confirm the harmful extension.

Do not define susceptibility by subsequently observing excess errors. Under randomized donor-paired control, ligand-neutralization and inducible IL11RA-loss conditions, compare characterized nonlethal lesion classes at matched genomic sites. Characterize initial break-end structure and chemistry, clustered or associated damage, complexity, local chromatin and replication context, lesion induction timing and burden. Equal break counts alone are insufficient. Combine a defined-break reporter with direct measurements at endogenous loci, including matched-site induced lesions and separately characterized ordinary endogenous damage where feasible. Follow lesion processing over time: treatment-induced end processing may itself mediate repair choice and must not automatically be matched away. Estimate the total treatment effect separately from repair accuracy under experimentally comparable initial substrates. Retain unchallenged cultures and the complete randomized starting population. The focal prediction is excess de novo structural repair errors for comparable initial lesion classes before differential expansion explains the result, with orthogonal IL-11 perturbations and a validated physiological, perturbation-compatible rescue reversing that excess. Orthogonal polymerase-theta perturbation should identify its contribution while accurate repair, other erroneous repair, persistent breaks, arrest, death and lineage loss remain accounted for per initial lesion and starting cell; descendant-level estimates are additional denominators. A reduced microhomology signature accompanied by worse unresolved damage or lineage survival does not demonstrate improved fidelity. The substrate/selection alternative predicts that differences follow lesion characteristics, lesion production, division history or lineage recovery, with equivalent accuracy for comparable substrates. If initial substrates cannot be adequately characterized or controlled, fidelity versus substrate mediation remains unresolved. Separately demonstrate reduced inflammatory injury, adequate early epithelial replacement and mature function, and preserved laboratory pathogen clearance at the same exposure. A fidelity defect alone supports only part of the frozen conjunction. Sensitive bounded equivalence constrains the prospectively defined population and tested lesion classes; it does not justify retrospectively excluding nonresponders. Receptor competition, communication defects and immune injury may coexist or lie upstream.

Disrupted interleukin-11 feedback may uncouple epithelial and stromal repair predicts instead: First identify a native responsive older-human lung epithelial–stromal sender–receiver pair. Independently perturb sender repair state across independently varied receiver starting states while controlling initial injury, matrix, nutrients and nonspecific support. Measure whether endogenous IL-11 output changes with sender state and whether selective sender IL-11 loss and receiver IL11RA loss interrupt the attributable response, with appropriate perturbation-alone and restoration controls. Monitor other secretions, nutrient changes, matrix changes and material transport. Then randomize correct alignment versus mismatch between actual partner state and delivered IL-11-dependent signal. Compare contingent signals with yoked signals from independently assigned, appropriately matched partners, shuffled signals and state-independent schedules. Balance waveform amplitude, duration, integrated exposure, pulse statistics and relevant delay distributions where feasible, while retaining state–signal alignment as the changed variable. Measure realized receptor activation and adaptation without forcing complete mediator histories to equality. The focal prediction is that mismatch impairs complementary mature differentiation and barrier recovery and correct alignment reverses this penalty while isolated competence and lower mean inflammatory signaling remain separately verified. A favorable separation additionally requires maintained reduction in actual inflammatory injury during rescue, with cell-specific exposure, peaks and duration assessed; a lower average can conceal damaging local pulses. Equivalent recovery with an appropriately chosen state-independent schedule after receiver readiness, shared injury history and support are addressed favors the alternative that actual partner state adds no necessary guidance. Unmatched replay superiority, equal integrated ligand and pulse-versus-tonic superiority are insufficient. Demonstrated endogenous feedback supports the biological coupling claim but does not establish novelty beyond reciprocal paracrine support or validate the consensus equation. For the model, calibrate coordinates and parameters independently and predict held-out changes in sender state, communication edges, delays and mature functional recovery; compare these predictions with receiver-only exposure/support models.

Interleukin-11 may reflect injury while exerting little control over human aging predicts instead: Test limited benefit and limited harm separately after a prospectively justified transient interval. At demonstrated tissue exposure, validated damage and functional trajectories should lie within prespecified consequential equivalence bounds, while repair, pathogen control and adverse channels independently meet their own bounds. Aggregate nonsignificance supports neither neutrality nor cancellation. If a candidate cost appears, use randomized control C, blockade B, rescue alone R and blockade-plus-rescue BR arms. Verify comparable blockade exposure and target engagement in B and BR, demonstrate adverse-mediator removal, and measure the rescue's independent effects. For Y oriented so that higher is better, estimate Δ0=Y_B−Y_C, ΔR=Y_BR−Y_R and interaction I=ΔR−Δ0. A favorable BR−B contrast does not identify blockade benefit; a favorable ΔR or interaction does not alone identify cancellation. The prediction that no consequential blockade benefit emerges under rescue is conditional on rescue preserving the relevant biological context, beneficial pathways and effect modifiers apart from removing a demonstrated blockade-induced harmful component. Test that preservation using direct mediator, cell-state, exposure and beneficial-channel measurements; rescue specificity by itself does not establish it. If rescue creates a new permissive state or interaction, benefit under rescue remains compatible with neutrality in the original setting. To support cancellation, demonstrate beneficial and harmful effects of blockade before rescue at the same exposure and relevant duration, then show selective removal of the harmful component while the beneficial route remains operative. Even with a factorial interaction, alternative synergy requires consideration. Failure to uncover benefit remains inconclusive when rescue is incomplete, context changes, exposure differs, precision is inadequate or follow-up is too short. Marker behavior, disease-specific amplification and redundancy require additional causal tests and are not identified by equivalence alone.

Interleukin-11 blockade may change displayed self-peptides and trigger immune injury predicts instead: First establish epithelial IL-11 responsiveness and a reproducible change in endogenous displayed self-peptide species under orthogonal epithelial IL-11 perturbations. Identify peptide sequence, relevant modifications and presenting HLA molecule. Compare baseline and treated samples with quantitative recovery controls, targeted baseline measurements and explicit detection limits. Baseline non-detection cannot establish absolute absence. Constrain baseline abundance and compare it with independently characterized recognition over physiological display ranges, testing whether increased abundance of an unchanged species can explain recognition. If that account remains plausible, report identity change as unresolved; do not count new detection as confirmation or reject broader antigen-specific harm. At comparable cell composition and total presentation, the full chain predicts altered proteasomal processing before the repertoire change, recognition by a baseline memory population with independently demonstrated cognate specificity, and then selective killing. Measure source proteins, direct cleavage products, transport/loading, HLA composition, turnover and cell state. Selective processing intervention should prevent the identity change and attributable injury while preserving epithelial fitness; physiological downstream reconstitution should restore the specified peptide–HLA complex and recognition. Broad proteasome inhibition is insufficient. Separately remove and restore the implicated peptide–HLA–T-cell-receptor interaction at endogenous-range display, preserving source-protein function and IL-11 blockade. Include epithelial-only, T-cell-only, coculture, perturbation-alone and pretreatment/washout controls with residual drug and pathway-state measurements. Demonstrate baseline memory phenotype, specificity, tissue access and response under prospectively defined physiological activation support; strong artificial stimulation cannot establish the in-tissue conjunction. Measure preserved intrinsic repair, adequate laboratory pathogen killing and reduced soluble inflammatory markers separately. Follow repeated killing, replacement, immune restraint and barrier function before claiming persistent injury. Identity change without processing mediation leaves the proteasomal link open; antigen-specific killing without an identified switch supports only a partial or alternative route. Injury independent of the specified recognition pair favors stress, bystander activation or generalized susceptibility.

SCOUT from transplant immunology and immunopeptidomics, conditional: In a prospectively specified susceptible population of aging-human epithelia, IL-11 blockade may change proteasomal processing and thereby change the identity of displayed self-peptides at comparable cell composition and total antigen-presentation abundance. Previously quiescent, pre-existing cognate autoreactive memory T cells could recognize those altered identities and impose repeated epithelial injury despite intact intrinsic repair capacity, adequate pathogen killing and reduced soluble inflammatory markers. If injury exceeds epithelial replacement and immune restraint and produces persistent functional damage, it could worsen particular SPV_3 clinical transitions and offset an independently demonstrated beneficial effect. Peptide identity is the frozen switch; increased quantity of already displayed peptides is an alternative. Processing, identity change, physiological recognition, killing, persistence and clinical consequence remain separately testable links. Finite baseline sampling may leave the identity distinction unresolved without disproving a broader antigen-specific injury mechanism.

Identify peptide sequence, relevant modifications and presenting HLA molecule. Compare baseline and treated samples with quantitative recovery controls, targeted baseline measurements and explicit detection limits. Baseline non-detection cannot establish absolute absence. Constrain baseline abundance and compare it with independently characterized recognition over physiological display ranges, testing whether increased abundance of an unchanged species can explain recognition. If that account remains plausible, report identity change as unresolved; do not count new detection as confirmation or reject broader antigen-specific harm. At comparable cell composition and total presentation, the full chain predicts altered proteasomal processing before the repertoire change, recognition by a baseline memory population with independently demonstrated cognate specificity, and then selective killing. Measure source proteins, direct cleavage products, transport/loading, HLA composition, turnover and cell state. Selective processing intervention should prevent the identity change and attributable injury while preserving epithelial fitness; physiological downstream reconstitution should restore the specified peptide–HLA complex and recognition. Broad proteasome inhibition is insufficient. Separately remove and restore the implicated peptide–HLA–T-cell-receptor interaction at endogenous-range display, preserving source-protein function and IL-11 blockade. Include epithelial-only, T-cell-only, coculture, perturbation-alone and pretreatment/washout controls with residual drug and pathway-state measurements. Demonstrate baseline memory phenotype, specificity, tissue access and response under prospectively defined physiological activation support; strong artificial stimulation cannot establish the in-tissue conjunction. Measure preserved intrinsic repair, adequate laboratory pathogen killing and reduced soluble inflammatory markers separately. Follow repeated killing, replacement, immune restraint and barrier function before claiming persistent injury. Identity change without processing mediation leaves the proteasomal link open; antigen-specific killing without an identified switch supports only a partial or alternative route. Injury independent of the specified recognition pair favors stress, bystander activation or generalized susceptibility.

Do not define susceptibility by subsequently observing excess errors. Under randomized donor-paired control, ligand-neutralization and inducible IL11RA-loss conditions, compare characterized nonlethal lesion classes at matched genomic sites. Characterize initial break-end structure and chemistry, clustered or associated damage, complexity, local chromatin and replication context, lesion induction timing and burden. Equal break counts alone are insufficient. Combine a defined-break reporter with direct measurements at endogenous loci, including matched-site induced lesions and separately characterized ordinary endogenous damage where feasible. Follow lesion processing over time: treatment-induced end processing may itself mediate repair choice and must not automatically be matched away. Estimate the total treatment effect separately from repair accuracy under experimentally comparable initial substrates. Retain unchallenged cultures and the complete randomized starting population. The focal prediction is excess de novo structural repair errors for comparable initial lesion classes before differential expansion explains the result, with orthogonal IL-11 perturbations and a validated physiological, perturbation-compatible rescue reversing that excess. Orthogonal polymerase-theta perturbation should identify its contribution while accurate repair, other erroneous repair, persistent breaks, arrest, death and lineage loss remain accounted for per initial lesion and starting cell; descendant-level estimates are additional denominators. A reduced microhomology signature accompanied by worse unresolved damage or lineage survival does not demonstrate improved fidelity. The substrate/selection alternative predicts that differences follow lesion characteristics, lesion production, division history or lineage recovery, with equivalent accuracy for comparable substrates. If initial substrates cannot be adequately characterized or controlled, fidelity versus substrate mediation remains unresolved. Separately demonstrate reduced inflammatory injury, adequate early epithelial replacement and mature function, and preserved laboratory pathogen clearance at the same exposure. A fidelity defect alone supports only part of the frozen conjunction. Sensitive bounded equivalence constrains the prospectively defined population and tested lesion classes; it does not justify retrospectively excluding nonresponders. Receptor competition, communication defects and immune injury may coexist or lie upstream.

Disrupted interleukin-11 feedback may uncouple epithelial and stromal repair predicts instead: First identify a native responsive older-human lung epithelial–stromal sender–receiver pair. Independently perturb sender repair state across independently varied receiver starting states while controlling initial injury, matrix, nutrients and nonspecific support. Measure whether endogenous IL-11 output changes with sender state and whether selective sender IL-11 loss and receiver IL11RA loss interrupt the attributable response, with appropriate perturbation-alone and restoration controls. Monitor other secretions, nutrient changes, matrix changes and material transport. Then randomize correct alignment versus mismatch between actual partner state and delivered IL-11-dependent signal. Compare contingent signals with yoked signals from independently assigned, appropriately matched partners, shuffled signals and state-independent schedules. Balance waveform amplitude, duration, integrated exposure, pulse statistics and relevant delay distributions where feasible, while retaining state–signal alignment as the changed variable. Measure realized receptor activation and adaptation without forcing complete mediator histories to equality. The focal prediction is that mismatch impairs complementary mature differentiation and barrier recovery and correct alignment reverses this penalty while isolated competence and lower mean inflammatory signaling remain separately verified. A favorable separation additionally requires maintained reduction in actual inflammatory injury during rescue, with cell-specific exposure, peaks and duration assessed; a lower average can conceal damaging local pulses. Equivalent recovery with an appropriately chosen state-independent schedule after receiver readiness, shared injury history and support are addressed favors the alternative that actual partner state adds no necessary guidance. Unmatched replay superiority, equal integrated ligand and pulse-versus-tonic superiority are insufficient. Demonstrated endogenous feedback supports the biological coupling claim but does not establish novelty beyond reciprocal paracrine support or validate the consensus equation. For the model, calibrate coordinates and parameters independently and predict held-out changes in sender state, communication edges, delays and mature functional recovery; compare these predictions with receiver-only exposure/support models.

Interleukin-11 may reflect injury while exerting little control over human aging predicts instead: Test limited benefit and limited harm separately after a prospectively justified transient interval. At demonstrated tissue exposure, validated damage and functional trajectories should lie within prespecified consequential equivalence bounds, while repair, pathogen control and adverse channels independently meet their own bounds. Aggregate nonsignificance supports neither neutrality nor cancellation. If a candidate cost appears, use randomized control C, blockade B, rescue alone R and blockade-plus-rescue BR arms. Verify comparable blockade exposure and target engagement in B and BR, demonstrate adverse-mediator removal, and measure the rescue's independent effects. For Y oriented so that higher is better, estimate Δ0=Y_B−Y_C, ΔR=Y_BR−Y_R and interaction I=ΔR−Δ0. A favorable BR−B contrast does not identify blockade benefit; a favorable ΔR or interaction does not alone identify cancellation. The prediction that no consequential blockade benefit emerges under rescue is conditional on rescue preserving the relevant biological context, beneficial pathways and effect modifiers apart from removing a demonstrated blockade-induced harmful component. Test that preservation using direct mediator, cell-state, exposure and beneficial-channel measurements; rescue specificity by itself does not establish it. If rescue creates a new permissive state or interaction, benefit under rescue remains compatible with neutrality in the original setting. To support cancellation, demonstrate beneficial and harmful effects of blockade before rescue at the same exposure and relevant duration, then show selective removal of the harmful component while the beneficial route remains operative. Even with a factorial interaction, alternative synergy requires consideration. Failure to uncover benefit remains inconclusive when rescue is incomplete, context changes, exposure differs, precision is inadequate or follow-up is too short. Marker behavior, disease-specific amplification and redundancy require additional causal tests and are not identified by equivalence alone.

Blocking interleukin-11 may free shared receptors to sustain harmful competing signals predicts instead: In a characterized older-human epithelial population under fixed defined ligands, an occupancy-releasing blocker should produce a quantitatively compatible loss of gp130 from IL-11 complexes and gain in specified competing complexes within the same accessible pool. Resolve individual cells and relevant membrane compartments with sufficient temporal resolution to establish exchange compatibility before the competing signal and functional cost. Reciprocal population or whole-cell averages from different subpopulations or disconnected compartments are insufficient. Use convergent minimally perturbing complex and localization measurements and, where validated, tracking of component movement or a pool-selective perturbation to test access and exchange. Account for free, other-bound, incoming, internalized and recycled components rather than assume direct one-for-one transfer. Compare blocker modalities at comparable IL-11 inhibition; occupancy-retaining inhibition need not redistribute gp130. Independently demonstrate a limiting range where additional accessible surface gp130 increases competing-complex assembly and a nonlimiting range where further increases do not materially increase assembly, with adequate precision and unsaturated detection. Independently verify that downstream and functional readouts retain responsive range. Quantify receptor abundances, ratios, localization, baseline complexes and trafficking across the manipulation. Only the conjunction of same-pool allocation, validated limitation and its relief, responsive readouts and functional mediation supports competition. Controlled occupancy restoration should reverse allocation, subject to controls for its effects on signaling and trafficking. Competing-receptor interruption should remove the attributable cost while IL-11 suppression persists, with interruption-alone controls. Rescue or attenuation at high gp130 alone does not distinguish allocation from feedback, saturation or trafficking. Follow the acute step into sustained harmful differentiation or function and post-transient deterioration; neutral, beneficial or transient allocation does not confirm the harmful extension.